CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its registered direct offering announced on October 21, 2025, for the purchase and sale of 1,750,000 common shares (the “Common Shares”) (or pre-funded warrants (the “Pre-Funded Warrants”) in lieu the ...

REHOVOT, Israel and Hoboken, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate in the Stifel 2025 Healthcare Conference, to be held to be held at the Lotte New York Palace Hotel, New-York, NY on November 11–13, 2025. Mr. London is sched ...

Core Insights - Lifecore Biomedical has signed an agreement to transfer commercial manufacturing of a leading injectable pharmaceutical product to its facilities, becoming the supplier of choice for this product after meeting regulatory requirements [1][2] - This marks the second agreement with the same multinational organization in recent months, indicating Lifecore's growing reputation for quality and reliability in sterile injectables [1][2] - Additionally, Lifecore has entered into a pre-clinical formulation development agreement with an early-stage biotech company, further expanding its early-stage program pipeline [2] Company Strategy - The commercial site transfer is part of Lifecore's growth strategy to expand its CDMO business and build long-term partnerships with leading global pharmaceutical companies [2] - The new agreement will broaden Lifecore's commercial customer base and increase capacity utilization while allowing entry into new modalities [2] - Lifecore aims to capitalize on strong industry momentum and strengthen its position as a trusted U.S.-based CDMO partner [3] Company Background - Lifecore Biomedical is a fully integrated CDMO specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [4] - The company has over 40 years of expertise and serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [4]

TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) is pleased to provide an update on the ongoing drilling program at the Company’s Mercur Gold Project (“Mercur”) in Utah and the Beartrack-Arnett Gold Project (“Beartrack-Arnett”) in Idaho. Highlights Mobilized a new core rig to Beartrack-Arnett bringing the total number of rigs drilling on the Company’s projects to four.At Mercur, received assay results from 16 additional drill holes with ...

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using ...

Coincides with Release of ACM Shanghai Third Quarter 2025 ResultsFREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer and panel processing solutions for semiconductor and advanced packaging applications, today announces expectations for preliminary unaudited revenue and total shipments for the third quarter of 2025. Today’s release coincides with the as-scheduled release of unaudited financial results by ACM Research (Shanghai), Inc., ACM’ ...

The Product Expands Grayscale’s Market-Leading Position with the Broadest Suite of Digital Asset ETPs in the U.S.STAMFORD, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Grayscale Investments®, the world’s largest digital asset-focused investment platform*, today announced that Grayscale Solana Trust ETF (Ticker: GSOL) has begun trading on NYSE Arca as an ETP, making it the first of Grayscale's staking products to uplist under the new generic listing standards approved by the U.S. Securities and Exchange Commissi ...

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation as a presenting company at BIO-Europe 2025. The event, Europe’s premier life sciences partnering conference, will take place November 3–5, 2025, at the Vienna Exhibition and Congress C ...

GOLETA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ:ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum computing, today announced it will issue its financial results for the first quarter of fiscal 2026, which ended September 30, 2025, after the U.S. financial markets close on Wednesday, November 12, 2025. That same day, Aeluma will host a conference call at 2:00 p.m. Pacifi ...

RIDGEFIELD, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) (the “Company” or “Chefs’”), a premier distributor of specialty food products in the United States, the Middle East, and Canada, today reported financial results for its third quarter ended September 26, 2025. Financial highlights for the third quarter of 2025: Net sales increased 9.6% to $1,021.3 million for the third quarter of 2025 from $931.5 million for the third quarter of 2024.GAAP net income was $19.1 mill ...